Get Involved
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Study Purpose
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that:
- - is advanced or metastatic (spread to other parts of the body); - has a certain type of abnormal gene called "BRAF"; and.
- - has not received prior treatment.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Male or female participants ≥ 18 years at the time of informed consent.
- - Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- - Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition.
- - Presence of at least 1 measurable lesion as detected by radiological and/or photographic methods according to RECIST v1.1.
- - ECOG performance status 0 or 1.
- - Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked [European conformity] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory.
- - Submission of adequate tumor tissue (archival or newly obtained; block or slides to the sponsor central laboratory(ies) during the screening period and prior to enrollment (SLI)/randomization (Phase 3).
- - Have not received prior first-line systemic therapy for metastatic or unresectable locally advanced melanoma.
- - Adequate bone marrow function, hepatic and renal function.
- - Capable of giving signed informed consent.
- - Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study (including, but not limited to, a participant who is rapidly progressing or has clinically significant tumor related symptoms, in the judgment of the investigator).
- - Mucosal or ocular melanoma.
- - Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
- - Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
- - Unable to swallow, retain, and absorb oral medications.
- - Impairment of GI function or disease which may significantly alter the absorption of oral study intervention (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, including malabsorption syndrome secondary to prior GI surgery).
- - Clinically significant cardiovascular diseases, - History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to enrollment (SLI)/randomization (Phase 3).
- - History or current evidence of RVO or current risk factors for RVO (eg, uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes) - Concurrent neuromuscular disorder that is associated with the potential of elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
- - Current noninfectious pneumonitis or history of noninfectious pneumonitis requiring steroids, or history of radiation pnuemonitis.
- - Evidence of HBV or HCV infection.
- - Known history of a positive test for HIV or known AIDS.
- - Any active infection requiring systemic therapeutic treatment within 2 weeks prior to enrollment (SLI)/ randomization (Phase 3).
- - Participants with prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases.
- - Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason ≤ 6 prostate cancer.
- - Participants who previously received and subsequently discontinued encorafenib and/or binimetinib and/or anti-PD-1/-L1 due to severe toxicity.
- - For participants in the SLI only: Current use or anticipated need for food or drugs that are known moderate or strong CYP3A4 inhibitors during screening and through the DLT-evaluation period.
- - Participant has not recovered to Grade ≤ 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before enrollment (SLI)/ randomization (Phase 3).
- - Receipt of protocol defined medications or treatments outside of required intervals before enrollment (SLI)/randomization (Phase 3): - Previous administration with an investigational drug ≤ 6 months prior to enrollment (SLI)/randomization (Phase 3).
- - Known sensitivity or contraindication to any component of study intervention (encorafenib, binimetinib and pembrolizumab), or their excipients.
- - Pregnant, confirmed by a positive β-hCG laboratory test result, or is breastfeeding (lactating).
- - Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT04657991 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Pfizer |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Pfizer CT.gov Call Center |
| Principal Investigator Affiliation | Pfizer |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Mexico, New Zealand, Norway, Poland, Russian Federation, Slovakia, South Africa, Spain, Switzerland, Turkey, Ukraine, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Melanoma |
| Study Website: | View Trial Website |
This study will compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma. The study will have an open-label safety lead-in (SLI) phase to determine the safety recommend Phase 3 dose (RP3D) and pharmacokinetics (PK) of encorafenib and binimetinib plus pembrolizumab combination therapy prior to initiation of the randomized Phase 3 part of the study. Two dose levels of encorafenib in combination with binimetinib plus pembrolizumab will be explored in parallel. A minimum of 12 evaluable participants will be enrolled per dose level. During the double-blind randomized Phase 3 part of the study, approximately 216 eligible participants will be randomized in a 1:1 ratio to the Triplet Arm (at RP3D determined in the SLI) or Control Arm (approximately 108 participants per arm). Randomization will be stratified by prior systemic adjuvant therapy and stage of disease by AJCC (ED8).
Arms
Experimental: Triplet Arm
Encorafenib and Binimetinib in combination with Pembrolizumab
Active Comparator: Control Arm
Pembrolizumab
Interventions
Drug: - Encorafenib
Encorafenib
Drug: - Binimetinib
Binimetinib
Drug: - Pembrolizumab
Pembrolizumab
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
UCLA - Hematology/Oncology - Administrative Office
Los Angeles, California, 90024
Status
Address
Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug
Los Angeles, California, 90095
Status
Address
Ronald Reagan UCLA Medical Center, Drug Information Center, Dept. of Pharmaceutical Services (Main O
Los Angeles, California, 90095
Status
Address
UCLA Hematology/Oncology - Westwood (Building 100)
Los Angeles, California, 90095
Status
Address
UCHealth Sue Anschutz-Rodgers Eye Center
Aurora, Colorado, 80045
Status
Address
University of Colorado Denver CTO/CTRC
Aurora, Colorado, 80045
Status
Address
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, Colorado, 80045
Status
Address
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado, 80045
Status
Address
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, Colorado, 80045
Status
Address
Florida Cancer Specialists
Cape Coral, Florida, 33909
Status
Address
Florida Cancer Specialists
Fort Myers, Florida, 33901
Status
Address
AdventHealth Orlando Infusion Center
Orlando, Florida, 32804
Status
Address
AdventHealth Orlando, Investigational Drug Services
Orlando, Florida, 32804
Status
Address
AdventHealth Orlando
Orlando, Florida, 32804
Status
Address
Advocate Medical Group-Park Ridge, Luther Lane-Oncology
Park Ridge, Illinois, 60068
Status
Address
The University of Kansas Cancer Center
Westwood, Kansas, 66205
Status
Address
Massachusetts General Hospital
Boston, Massachusetts, 02114
Status
Address
Ophthalmic Consultants of Boston Inc (OCB)
Boston, Massachusetts, 02114
Status
Address
Revive Research Institute, Inc.
Farmington Hills, Michigan, 48334
Status
Address
Michigan Health Professionals
Farmington Hills, Michigan, 48344
Status
Address
St. Vincent Healthcare
Billings, Montana, 59101
Status
Address
St. Vincent Frontier Cancer Center
Billings, Montana, 59102
Status
Address
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
Status
Address
University of Cincinnati Medical Center
West Chester, Ohio, 45069
Status
Address
University of Tennessee Medical Center
Knoxville, Tennessee, 37920
Status
Address
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Status
Address
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203
Status
Address
Texas Oncology - Carrollton
Carrollton, Texas, 75010
Status
Address
North Dallas Eye Associates
Flower Mound, Texas, 75028
Status
Address
Texas Oncology - Flower Mound
Flower Mound, Texas, 75028
Status
Address
Baylor Clinic
Houston, Texas, 77030
Status
Address
Baylor College of Medicine Medical Center
Houston, Texas, 77030
Status
Address
Baylor College of Medicine
Houston, Texas, 77030
Status
Address
CHI St. Luke's Health Baylor College of Medicine Medical Center
Houston, Texas, 77030
Status
Address
Harris Health System - Ben Taub Hospital
Houston, Texas, 77030
Status
Address
Harris Health System - Smith Clinic
Houston, Texas, 77054
Status
Address
Dan Brown O.D.
Paris, Texas, 75460
Status
Address
Texas Oncology-Paris
Paris, Texas, 75460
Status
Address
Baylor Scott & White Medical Center - Temple
Temple, Texas, 76508
Status
Address
Utah Cancer Specialists
American Fork, Utah, 84003
Status
Address
Utah Cancer Specialists
Bountiful, Utah, 84010
Status
Address
Utah Cancer Specialists
Layton, Utah, 84041
Status
Address
Utah Cancer Specialists
Murray, Utah, 84157
Status
Address
Utah Cancer Specialists
Ogden, Utah, 84405
Status
Address
Utah Cancer Specialists
Provo, Utah, 84604
Status
Address
Utah Cancer Specialists
Salt Lake City, Utah, 84102
Status
Address
Utah Cancer Specialists
Salt Lake City, Utah, 84106
Status
Address
Utah Cancer Specialists
West Jordan, Utah, 84088
Status
Address
Utah Cancer Specialists
West Valley City, Utah, 84119
International Sites
Status
Address
Instituto Alexander Fleming
Caba, Buenos Aires, C1426ANZ
Status
Address
Clinica Viedma S. A
Viedma, RÍO Negro, 8500
Status
Address
Instituto de Oncologia de Rosario
Rosario, Santa FE, S2000KZE
Status
Address
Universitätsklinikum St. Pölten
St. Pölten, Niederösterreich, 3100
Status
Address
Ordensklinikum Linz GmbH Elisabethinen
Linz, Oberösterreich, 4020
Status
Address
Medizinische Universität Wien
Vienna, Wien, 1090
Status
Address
Medizinische Universität Graz
Graz, , 8036
Status
Address
UZ Brussel
Brussels, Bruxelles-capitale, Région DE, 1090
Status
Address
UZ Gent
Gent, Oost-vlaanderen, 9000
Status
Address
AZ Sint-Jan Brugge-Oostende AV
Brugge, West-vlaanderen, 8000
Status
Address
Cliniques universitaires Saint-Luc
Brussels, , 1200
Status
Address
Centre Hospitalier de Jolimont
Haine Saint Paul, , 7100
Status
Address
VITAZ
Sint-Niklaas, , 9100
Status
Address
Instituto de Oncologia do Paraná - IOP Matriz Mateus Leme
Curitiba, Paraná, 80520-174
Status
Address
Instituto de Oncologia do Paraná - IOP Oncoville
Curitiba, Paraná, 82305-100
Status
Address
Hospital de Clinicas de Porto Alegre
Porto Alegre, RIO Grande DO SUL, 90035-903
Status
Address
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Rio de Janeiro, RJ, 20220-410
Status
Address
Hospital de Clínicas de Passo Fundo
Passo Fundo, RS, 99010-260
Status
Address
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, SÃO Paulo, 14784-400
Status
Address
Hospital Sírio-Libanês - Unidade Bela Vista
São Paulo, , 01308-050
Status
Address
Complex Oncology Center - Plovdiv EOOD
Plovdiv, , 4004
Status
Address
Complex Oncology Center-Ruse EOOD
Ruse, , 7002
Status
Address
Medical Center Nadezhda Clinical EOOD
Sofia, , 1373
Status
Address
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD
Sofia, , 1407
Status
Address
Umhato Ead
Sofia, , 1756
Status
Address
Kingston Health Sciences Centre-Kingston General Hospital Site
Kingston, Ontario, K7L 2V7
Status
Address
CIUSSS du Saguenay-Lac-Saint-Jean
Chicoutimi, Quebec, G7H 5H6
Status
Address
McGill University Health Centre - Glen Site
Montreal, Quebec, H4A 3J1
Status
Address
Saskatoon Cancer Center
Saskatoon, Saskatchewan, S7N4H4
Status
Address
Fakultni nemocnice Olomouc
Olomouc, Olomoucký KRAJ, 779 00
Status
Address
Olomouc University Hospital
Olomouc, Olomoucký KRAJ, 779 00
Status
Address
Masarykuv Onkologicky Ustav
Brno, , 656 53
Status
Address
Fakultni nemocnice Hradec Kralove
Hradec Kralove, , 500 05
Status
Address
Fakultni nemocnice Ostrava
Ostrava-Poruba, , 708 52
Status
Address
Všeobecná fakultní nemocnice
Praha 2, , 128 08
Status
Address
Fakultni nemocnice Bulovka
Praha 8-Liben, , 180 81
Status
Address
Tampereen yliopistollinen sairaala
Tampere, Pirkanmaa, 33520
Status
Address
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
Helsinki, , 00029
Status
Address
CHG Le Mans
Le Mans, Cedex 9, 72037
Status
Address
Chu Charles Nicolle
Rouen, Haute-normandie, 76031
Status
Address
CHU de Lille - Hôpital Claude Huriez Service
Lille, Nord, 59037
Status
Address
CHU d'Amiens - Hôpital Nord
Amiens, , 80054
Status
Address
CHU d'Angers
Angers, , 49000
Status
Address
Hôpital Saint André
Bordeaux, , 33075
Status
Address
Hôpital Ambroise Paré
Boulogne-Billancourt, , 92100
Status
Address
Hôpital Ambroise Paré
Boulogne-Billancourt, , 92104
Status
Address
CHU de Dijon Bourgogne
Dijon Cedex, , 21079
Status
Address
CHU Grenoble Alpes
La Tronche, , 38700
Status
Address
CHG Le Mans
Le Mans, , 72037
Status
Address
CHU de Lille - Hôpital Claude Huriez Service
Lille, , 59037
Status
Address
Hôpital de la Timone
Marseille, , 13385
Status
Address
Hôpital Lyon Sud
Pierre-Bénite, , 69310
Status
Address
CHU de Poitiers
Poitiers, , 86000
Status
Address
Hôpital Charles Nicolle - CHU de Rouen
Rouen, , 76031
Status
Address
CHU de Saint-Etienne - Hôpital Nord
Saint-Etienne Cedex 2, , 42055
Status
Address
Gustave Roussy
Villejuif, , 94800
Status
Address
Universitaetsklinikum Tuebingen
Tuebingen, Baden-württemberg, 72076
Status
Address
Universitaetsklinikum Erlangen
Erlangen, Bayern, 91054
Status
Address
Klinik und Poliklinik für Dermatologie und Allergologie
München, Bayern, 80337
Status
Address
Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude
Buxtehude, Niedersachsen, 21614
Status
Address
Universitätsklinikum Bonn
Bonn, Nordrhein-westfalen, 53127
Status
Address
Johannes Wesling Klinikum Minden
Minden, Nordrhein-westfalen, 32429
Status
Address
Universitätsmedizin Johannes Gutenberg Universität Mainz
Mainz, Rheinland-pfalz, 55131
Status
Address
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Sachsen, 01307
Status
Address
Universitätsklinikum Leipzig
Leipzig, Sachsen, 04103
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel
Kiel, Schleswig-holstein, 24105
Status
Address
Universitätsklinikum Schleswig-Holstein
Lübeck, Schleswig-holstein, 23538
Status
Address
SRH Wald-Klinikum Gera
Gera, Thüringen, 07548
Status
Address
Charité Universitaetsmedizin Berlin - Campus Mitte
Berlin, , 10117
Status
Address
Vivantes Klinikum Neukölln
Berlin, , 12351
Status
Address
HELIOS Klinikum Erfurt
Erfurt, , 99089
Status
Address
Universitätsklinikum Essen (AöR)
Essen, , 45147
Status
Address
Universitaetsklinikum Halle - Universitaetsklinik und Poliklinik fuer Dermatologie und Venerologie
Halle, , 06120
Status
Address
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, , 20246
Status
Address
Medizinische Hochschule Hannover
Hannover, , 30625
Status
Address
Universitätsklinikum Heidelberg
Heidelberg, , 69120
Status
Address
University Hospital Muenster
Muenster, , 48149
Status
Address
Fachklinik Hornheide
Münster, , 48157
Status
Address
Klinikum Nürnberg Nord
Nürnberg, , 90419
Status
Address
Universitätsklinikum Regensburg
Regensburg, , 93053
Status
Address
General Hospital of Athens "Laiko"
Athens, Attikí, 11527
Status
Address
Laiko Hospital
Athens, Attikí, 11527
Status
Address
Metropolitan Hospital
Piraeus, Attikí, 185 47
Status
Address
University General Hospital of Heraklion
Heraklion, Irakleío, 71500
Status
Address
Bioclinic Thessalonikis Private Clinic Single Member S.A.
Thessaloniki, Kentrikí Makedonía, 546 22
Status
Address
Pécsi Tudományegyetem Klinikai Központ
Pécs, Baranya, 7632
Status
Address
Semmelweis Egyetem
Budapest, , 1085
Status
Address
Orszagos Onkologiai Intezet
Budapest, , 1122
Status
Address
Debreceni Egyetem Klinikai Kozpont
Debrecen, , 4032
Status
Address
Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, , 6720
Status
Address
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház
Szolnok, , 5004
Status
Address
Ha'emek Medical Center.
Afula, Hatsafon, 1834111
Status
Address
Soroka University Medical Center
Be'er-Sheva, , 8410101
Status
Address
Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
Jerusalem, , 9112001
Status
Address
Rabin Medical Center, Beilinson Hospital
Petah Tikva, , 4941492
Status
Address
The Chaim Sheba Medical Center
Tel Hashomer, , 5265601
Status
Address
Tel Aviv Sourasky Medical Center
Tel-Aviv, , 6423906
Status
Address
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Friuli Venezia Giulia, 33100
Status
Address
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, MI, 20133
Status
Address
Istituto Dermopatico dell'Immacolata (IDI-IRCCS)
Roma, RM, 00167
Status
Address
A.O.U.S. Policlinico "Le Scotte"
Siena, SI, 53100
Status
Address
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
Candiolo, Torino, 10060
Status
Address
Istituto Tumori Giovanni Paolo II
Bari, , 70124
Status
Address
IRCCS Ospedale Policlinico San Martino
Genova, , 16132
Status
Address
Istituto Europeo di Oncologia IRCCS
Milano, , 20141
Status
Address
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Napoli, , 80131
Status
Address
Istituto Oncologico Veneto IOV - IRCCS
Padova, , 35128
Status
Address
AO di Perugia - Ospedale S. Maria della Misericordia, S.C Oncologia Medica
Perugia, , 06132
Status
Address
Istituto Nazionale Tumori Regina Elena
Roma, , 00144
Status
Address
ONCARE Viaducto Nápoles
Benito Juárez, Ciudad DE México, 03810
Status
Address
Preparaciones Oncológicas S.C.
León, Guanajuato, 37178
Status
Address
I Can Oncology Center S.A. de C.V.
Monterrey, Nuevo LEÓN, 64710
Status
Address
BRCR Global Mexico - CDMX
Ciudad de México, , 01120
Status
Address
El Cielo Medical Center RSB, S.C
Puebla, , 72160
Status
Address
El Cielo Medical Center
Puebla, , 72160
Status
Address
New Zealand Clinical Research (Christchurch)
Christchurch, Canterbury, 8011
Status
Address
Palmerston North Hospital
Palmerston North, Manawatu, 4414
Status
Address
Auckland City Hospital
Auckland, , 1023
Status
Address
Akershus Universitetssykehus
Lørenskog, Akershus, 1474
Status
Address
Oslo universitetssykehus, Radiumhospitalet
Oslo, , 0379
Status
Address
Uniwersyteckie Centrum Kliniczne
Gdansk, , 80-214
Status
Address
Jagiellońskie Centrum Innowacji Sp. z o .o.
Krakow, , 30-348
Status
Address
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o .o.
Krakow, , 31-826
Status
Address
Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu
Poznan, , 60-780
Status
Address
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Warszawa, , 02-781
Status
Address
Private Medical Institution "Euromedservice"
Pushkin, Saint-petersburg, 196603
Status
Address
Ars Medika Center, LLC
Kaliningrad, ,
Status
Address
BIH of Omsk Region "Clinical Oncological Dispensary"
Omsk, , 644046
Status
Address
Eurocityclinic LLC
St.Petersburg, , 197022
Status
Address
Fakultná nemocnica s poliklinikou F.D. Roosevelta Banská Bystrica
Banska Bystrica, , 975 17
Status
Address
Onkologicky ustav sv. Alzbety, s.r.o.
Bratislava, , 812 50
Status
Address
Narodny onkologicky ustav
Bratislava, , 833 10
Status
Address
Vychodoslovensky onkologicky ustav, a.s.
Kosice, , 04191
Status
Address
Nemocnica na okraji mesta, n.o.
Partizanske, , 95801
Status
Address
POKO Poprad, s.r.o.
Poprad, , 058 01
Status
Address
Wits Clinical Research
Johannesburg, Gauteng, 2193
Status
Address
Sandton Oncology Medical Group (Pty) Ltd
Johannesburg, Gauteng, 2196
Status
Address
Drs Alberts, Bouwer and Jordaan Inc.
Pretoria, Gauteng, 0081
Status
Address
Mary Potter Oncology Centre
Pretoria, , 0181
Status
Address
CHUS - Hospital Clinico Universitario
Santiago De Compostela, A Coruna, 15706
Status
Address
ICO-Badalona Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916
Status
Address
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, 39008
Status
Address
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, 28222
Status
Address
Hospital Clinico Universitario Virgen de la Arrixaca
El Palmar, Murcia, 30120
Status
Address
Complejo Hospitalario De Navarra
Pamplona, Navarra, 31008
Status
Address
CHUAC-Hospital Teresa Herrera
A Coruña, , 15006
Status
Address
Hospital Universitari Vall D'Hebron, Servicio de Oncología Médica
Barcelona, , 08035
Status
Address
Hospital Clinic Barcelona
Barcelona, , 08036
Status
Address
Hospital de la Santa Creu i Sant Pau
Barcelona, , 08041
Status
Address
Hospital Universitario Reina Sofía
Cordoba, , 14004
Status
Address
Complejo Hospitalario de Jaen
Jaen, , 23007
Status
Address
Hospital Universitario Arnau de Vilanova
Lleida, , 25198
Status
Address
Hospital General Universitario Gregorio Marañón
Madrid, , 28007
Status
Address
Hospital Universitario Ramón y Cajal
Madrid, , 28034
Status
Address
Hospital Regional Universitario de Malaga - Hospital Civil
Málaga, , 29011
Status
Address
Hospital Universitario Virgen Macarena
Sevilla, , 41009
Status
Address
Hospital Universitario Virgen del Rocio
Sevilla, , 41013
Status
Address
Fundacion Instituto Valenciano de Oncologia
Valencia, , 46009
Status
Address
Hospital Universitario Miguel Servet
Zaragoza, , 50009
Status
Address
Kantonsspital Winterthur
Winterthur, , 8401
Status
Address
UniversitätsSpital Zürich
Zürich Flughafen, , 8058
Status
Address
Istanbul University Cerrahpasa Medical Faculty Hospital
Istanbul, İ̇stanbul, 34098
Status
Address
Medipol Mega Universite Hastanesi
İstanbul, İ̇stanbul, 34214
Status
Address
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, İ̇stanbul, 34722
Status
Address
Memorial Ankara Hastanesi
Ankara, , 06520
Status
Address
Ankara Şehir Hastanesi
Ankara, , 06800
Status
Address
Medical and diagnostic center of MedX-Ray International Group Limited Liability Company Israeli
Pliuty Village, KYIV Region, Obukhiv District, 08720
Status
Address
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council
Dnipro, , 49102
Status
Address
Municipal non-profit enterprise Khmelnytsky regional antitumor center of Khmelnytsky regional
Khmelnytskyi, , 29009
Status
Address
Municipal non-profit enterprise "Kyiv City Clinical Hospital No. 2" of the executive body of the
Kyiv, , 02094
Status
Address
National Cancer Institute
Kyiv, , 03022
Status
Address
Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Oncological Regional Therapeutical
Lviv, , 79031
Status
Address
Derzhavna ustanova Instytut zahalnoi ta nevidkladnoi khirurhii im.V.T.Zaitseva Natsionalnoi akademii
M. Kharkiv, , 61103
Status
Address
Komunalne nekomertsiine pidpryiemstvo Kharkivskoi oblasnoi rady "Oblasnyi klinichnyi spetsializovany
M. Kharkiv, , 61166
Status
Address
Municipal non-profit enterprise "Zaporizhzhia Regional Antitumor Center" Zaporizhzhya Regional Counc
Zaporizhzhia, , 69040
Status
Address
Nottingham University Hospitals NHS Trust
Nottingham, Nottinghamshire, NG5 1PB
Status
Address
St. Bartholomew's Hospital, Barts Health NHS Trust
London, , EC1A 7BE
Status
Address
Nottingham University Hospitals NHS Trust
Nottingham, , NG5 1PB
Status
Address
The South West Wales Cancer Institute, Swansea Bay University Health Board
Swansea, , SA2 8QA
